Vontobel Holding Ltd. Makes New Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Vontobel Holding Ltd. acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,326 shares of the company's stock, valued at approximately $291,000.

Several other institutional investors have also modified their holdings of the stock. NBC Securities Inc. purchased a new stake in TransMedics Group in the first quarter worth about $25,000. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group during the fourth quarter worth about $31,000. AlphaQuest LLC purchased a new position in shares of TransMedics Group in the fourth quarter worth $52,000. Rakuten Securities Inc. grew its stake in TransMedics Group by 68.3% during the 4th quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock valued at $84,000 after purchasing an additional 550 shares during the last quarter. Finally, Sava Infond d.o.o. purchased a new position in TransMedics Group during the 4th quarter worth approximately $94,000. 99.67% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares of the company's stock, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the transaction, the director owned 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 12,418 shares of company stock valued at $1,512,613. Insiders own 7.00% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Oppenheimer lifted their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Piper Sandler reissued an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group presently has a consensus rating of "Moderate Buy" and an average target price of $127.33.

TransMedics Group Stock Up 1.3%

NASDAQ:TMDX traded up $1.68 during trading hours on Wednesday, hitting $126.41. The company's stock had a trading volume of 636,287 shares, compared to its average volume of 1,366,035. The stock has a market capitalization of $4.28 billion, a P/E ratio of 92.95 and a beta of 2.06. The stock has a fifty day moving average of $123.67 and a 200-day moving average of $89.45. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The firm's revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.35 earnings per share. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.